They have one approved orphan drug and nothing else to speak of in the pipeline.
According to a recent PR:
They expect revenues of $15M to $25M for 2013 with 250 to 300 patients.
Next year, assuming EU approval, which is a big if, they expect $100M of revenues and breakeven.
If approval is granted in the EU they will pursue reimbursement on a country by country basis.
There are a lot of ifs just to reach breakeven.
The Company burns cash like an arsonist: $40 million in the past 9 months with no ongoing trials and no marketing expenses.
It will be difficult to get the EU countries to agree to the Company's outrageous reimbursement requests, IF it's even approved in the EU.